

(4)

D



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number: **0 601 191 A1**

(12)

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

(21) Application number: 93909411.6

(51) Int. Cl.⁵: C07D 221/18

(22) Date of filing: 23.04.93

(96) International application number:
PCT/JP93/00527

(97) International publication number:
WO 93/22286 (11.11.93 93/27)

(30) Priority: 24.04.92 JP 106482/92
22.12.92 JP 342710/92

(43) Date of publication of application:
15.06.94 Bulletin 94/24

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

(71) Applicant: KYOWA HAKKO KOGYO
KABUSHIKI KAISHA
6-1, Ohte-machi 1-chome
Chiyoda-ku Tokyo 100(JP)

(72) Inventor: SUZUKI, Fumio
18-4, Fujimidal, Mishima-shi
Shizuoka 411(JP)
Inventor: NAKASATO, Yoshisuke
1188, Shimotogari,
Nagazumi-cho
Sunto-gun, Shizuoka 411(JP)
Inventor: TSUMUKI, Hiroshi

1188, Shimotogari,
Nagazumi-cho
Sunto-gun, Shizuoka 411(JP)
Inventor: OHMORI, Kenji
2-14-3, Fuyodai, Mishima-shi
Shizuoka 411(JP)
Inventor: NAKAJIMA, Hiroshi
410-1-307, Nameri,
Nagazumi-cho
Sunto-gun, Shizuoka 411(JP)
Inventor: TAMURA, Tadafumi
3198-3, Ooka, Numazu-shi
Shizuoka 410(JP)
Inventor: SATO, Soichiro
564-5, Nakatogari,
Nagazumi-cho
Sunto-gun, Shizuoka 411(JP)


(74) Representative: VOSSIUS & PARTNER
Siebertstrasse 4
D-81675 München (DE)

EP 0 601 191 A1

(54) NOVEL TETRACYCLIC COMPOUND.

(57) A novel tetracyclic compound useful as an immuno-suppressant, represented by general formula (I), or a pharmacologically acceptable salt thereof wherein X¹ and X² may be the same or different from each other and each represents hydrogen or lower alkyl, and n represents an integer of 1 to 4.

EP 0 601 191 A1




(I).

Technical Field

The present invention relates to novel tetracyclic compounds which are useful as immunosuppressive agents.

Prior Art

A compound represented by the formula




(where R^1 represents CO_2H , etc.; R^2 and R^3 independently represent H, F, etc.; and R^4 and R^5 independently represent H, etc.) is disclosed in Japanese Published Unexamined Patent Application No. 233661/90 (US 4918077) as being effective as a cancer chemotherapeutic agent, and in WO 92/00739, it is mentioned as being useful as an immunosuppressive agent.

The compound sodium 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylate (Dup785) is disclosed in Japanese Published Unexamined Patent Application No. 313428/89 (US 5084462) as being useful as an immunosuppressive agent.

The compounds 5H-indeno[1,2-b]quinoline-6-carboxylic acid; 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid and 5,6,7,8-tetrahydrobenzo[7,8]cycloocta[1,2-b]quinoline-9-carboxylic acid have been reported, but their pharmacological effects are unknown [(Liebigs Ann. Chem., 610, 57 (1957)].

Disclosure of the Invention

According to the present invention, there are provided novel tetracyclic compounds represented by formula (I)



(wherein X^1 and X^2 independently represent hydrogen or lower alkyl; and n represents an integer of 1 to 4) and pharmaceutically acceptable salts thereof.

In the definition of the respective groups in formula (I), the lower alkyl includes straight-chain or branched alkyl group having 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertbutyl, pentyl, neopentyl, hexyl, etc.


The pharmaceutically acceptable salts of compound (I) include metal salts, ammonium salts, organic amine addition salts and amino acid addition salts.

As the pharmaceutically acceptable metal salts of Compound (I) include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salts and zinc salt; as the pharmaceutically acceptable ammonium salts include salts of ammonium and tetramethylammonium; as the pharmaceutically acceptable organic amine addition salts include addition salts with morpholine and piperidine; and as the pharmaceutically acceptable amino acid addition salt include addition salts with lysine, glycine and phenylalanine.

The processes for producing the compounds of the present invention are described below.

Process 1

Compound (I-a), Compound (I) wherein X^1 and X^2 are both hydrogen, can be obtained by the following reaction steps.



(In the above formulae, n has the same meaning as defined above.)

STEP 1:

Compound (III) can be obtained by treating Compound (II) with a dehydrating agent in the absence of a solvent usually at 50 to 120 °C for 1 to 6 hours.

The dehydrating agent includes polyphosphoric acid, methanesulfonic acid and sulfuric acid.

STEP 2:

Compound (IV) can be obtained by reacting Compound (III) with 2 to 3 equivalents of triethylsilane in trifluoroacetic acid usually at room temperature to 70 °C for 5 minutes to 6 hours.


STEP 3:

Compound (V) can be obtained by reacting Compound (IV) with 1 to 4 equivalents of chromic acid in a mixed solvent of acetic acid/propionic acid usually at 0 °C to room temperature for 1 to 6 hours.

STEP 4:

Compound (I-a) can be obtained by reacting Compound (V) with an equivalent amount of Compound (VI) (product of Aldrich Co.) in a mixed solvent of ethanol/water under the alkaline condition where potassium hydroxide, sodium hydroxide, etc. are used usually at room temperature to 100 °C for 12 to 120 hours.

Compound (II) can be obtained by the following reaction steps.



(In the above formulae, n has the same meaning as defined above.)

STEP 5:

Compound (IX) can be obtained by reacting Compound (VII) (product of Aldrich Co.) with an equivalent amount of Compound (VIII) in an inert solvent such as dichloromethane and dichloroethane in the presence of 2 equivalents of a Lewis acid such as aluminum trichloride usually at 0 °C to room temperature for 1 to 12 hours.


STEP 6:

Compound (X) can be obtained from Compound (IX) by the same method as in Step 2 above.

STEP 7:

Compound (II) can be obtained by reacting Compound (X) in a mixed solvent of dioxane/water under the alkaline condition where potassium hydroxide, sodium hydroxide, etc. are used usually at room temperature to 100 °C for 1 to 12 hours.

As an alternative method, Compound (II-a), wherein n in the starting Compound (II) is 2 or 3, can be obtained by the following reaction steps.



(In the above formulae, m represents 2 or 3.)


25 **STEP 8:**

Compound (XII) can be obtained from Compound (VII) (product of Aldrich Co.) and an equivalent amount of Compound (XI) (product of Aldrich Co.) by approximately the same method as in Step 5 above.

30 **STEP 9:**

Compound (II-a) can be obtained from Compound (XII) by approximately the same method as in Step 2 above.

Compound (V) can be obtained by the following reaction step.



50 (In the above formulae, n has the same meaning as defined above, Bu represents butyl, and Z represents bromine, iodine or trifluorosulfonyloxy.)


STEP 10:

55 Compound (V) can be obtained by reacting Compound (XIII) with 1 to 2 equivalents of Compound (XIV) in a solvent such as dimethylformamide, tetrahydrofuran and dioxane in the presence of a catalytic amount of a palladium complex usually at 60 to 120°C for 1 to 12 hours. If necessary, a salt such as lithium chloride or an oxidizing agent such as silver oxide may be added thereto.

Compound (XIII) may be synthesized by the known method [J. Org. Chem. 27, 70 (1962)] or a similar method. Also, compound (XIV) may be synthesized by the known method [Angew. Chem., Int. Ed. Engl., 25, 508 (1986)] or a similar method.

A compound wherein X^1 and/or X^2 in Compound (I) are lower alkyl may be obtained by the following Processes 2 to 4.

Process 2



(In the above formulae, n has the same meaning as defined above, and X^{1a} represents the lower alkyl in the definition of X^1 .)

STEP 11:

Compound (XV) can be obtained by reacting Compound (III) with an equivalent amount of an alkylphosphonium salt in a solvent such as tetrahydrofuran, dioxane, dimethylformamide and dimethylsulfoxide in the presence of a base usually at 0 to 120 °C for 5 minutes to 12 hours, and then carrying out catalytic hydrogenation with a catalyst such as palladium/carbon and platinum dioxide, in a solvent such as methanol, ethanol and acetic acid usually at 0 to 100 °C for 5 minutes to 12 hours.

As the base, *n*-butyl lithium, potassium *tert*-butoxide, sodium hydride, sodium hydroxide, potassium carbonate, triethylamine are exemplified.


As an alternative method of Step 11, Compound (XV) can be obtained by reacting Compound (III) with 1 to 5 equivalents of a Grignard reagent in a solvent such as ether, tetrahydrofuran and dioxane at -30 to 100 °C for 5 minutes to 12 hours, and then reacting the product with 1 to 2 equivalents of triethylsilane in trifluoroacetic acid usually at room temperature to 70 °C for 5 minutes to 6 hours.

STEP 12:

Compound (XVI) can be obtained from Compound (XV) by the same method as in Step 3 above.

STEP 13:

Compound (I-b) can be obtained from Compound (XVI) and Compound (VI) by the same method as in Step 4 above.

Process 3

(In the above formulae, X^{1a} and n have the same meanings as defined above and X^{2a} represents the lower alkyl in the definition of X^2 .)

STEP 14:

Compound (XVII) can be obtained by reacting Compound (II) with 2 to 10 equivalents of a Grignard reagent in a solvent such as ether, tetrahydrofuran and dioxane usually at -30 to 100°C for 5 minutes to 12 hours.

STEP 15:

Compound (XVIII) can be obtained by treating Compound (XVII) in an inert solvent such as dichloromethane and dichloroethane in the presence of an equivalent amount of a Lewis acid such as aluminum trichloride usually at 0°C to room temperature for 1 to 12 hours.


STEP 16:

Compound (XIX) can be obtained from Compound (XVIII) by the same method as in Step 3 above.

STEP 17:

Compound (I-c) can be obtained from Compound (XIX) and Compound (VI) by the same method as in Step 4 above.

Process 4



(In the above formulae, X^{1a} , X^2 and m have the same meanings as defined above.)

STEP 18:

Compound (XX) may be obtained by reacting Compound (III-a), Compound (III) wherein n is 2 or 3, with an alkyl halide such as methyl iodide and ethyl iodide in a solvent such as tetrahydrofuran, dioxane, dimethylformamide and dimethylsulfoxide in the presence of a base usually at 0 to 120 °C for 5 minutes to 12 hours.

As the base, sodium hydride, potassium tert-butoxide, sodium hydroxide, potassium carbonate are exemplified. If necessary, a quaternary ammonium halide such as tetrabutylammonium bromide or a phase-transfer catalyst such as 18-crown-6 or another crown ether may be added thereto.

As an alternative method of Step 18, Compound (XX) can be obtained by reacting Compound (III-a) with a secondary amine such as pyrrolidine and piperazine in a solvent such as benzene and toluene in the presence of *p*-toluenesulfonic acid usually under reflux for 1 to 12 hours, and then reacting the product with an alkyl halide such as methyl iodide and ethyl iodide in a solvent such as dioxane and dimethylformamide usually at room temperature to 100 °C for 5 minutes to 12 hours.

STEP 19:

Compound (XXI) can be obtained from Compound (XX) by the same method as in Step 2 above.

STEP 20:

Compound (XXII) can be obtained from Compound (XXI) by the same method as in Step 3 above.

STEP 21:

Compound (I-d) can be obtained from Compound (XXII) and Compound (VI) by the same method as in Step 4 above.

The intermediates and the desired compounds in the processes described above may be isolated and purified by purification methods conventionally used in organic synthetic chemistry, for example, filtration,


extraction, washing, drying, concentration, recrystallization, and various kinds of chromatography. The intermediates may also be subjected to the subsequent reaction without purification.

In the case where a salt of Compound (I) is desired and it is produced in the form of the desired salt, it may be subjected to purification as such. In the case where Compound (I) is produced in the free form and its salt is desired, it may be dissolved or suspended in an appropriate solvent, and then an acid or a base may be added thereto to the solution or suspension to form its salt.

Compound (I) and pharmaceutically acceptable salt thereof may be in the form of adducts with water or various solvents, which are also included in the scope of the present invention.

Specific examples of Compound (I) obtained by the respective processes are shown in Table 1.

Table 1



| Compound No. | n | X ¹ | X ² |
|--------------|---|---------------------------------|-------------------|
| 1 | 1 | H | H |
| 2 | 2 | H | H |
| 3 | 3 | H | H |
| 4 | 4 | H | H |
| 5 | 2 | 5-CH ₃ | H |
| 6 | 2 | 5-C ₂ H ₅ | H |
| 7 | 2 | 5-CH ₃ | 5-CH ₃ |
| 8 | 2 | 6-CH ₃ | H |
| 9 | 3 | 5-CH ₃ | H |
| 10 | 3 | 6-CH ₃ | H |
| 11 | 3 | 6-CH ₃ | 6-CH ₃ |

The pharmacological activities of Compound (I) are illustrated with the following test examples.

Test Example 1:

Plaque Forming Cell Assay

5 The plaque forming cell assay was carried out by the following manner with reference to the method of Jerne et al. [Science, 140, 405 (1963)] and the method of Yamamoto et al. [Drugs Experimental Clinical Research, III(1), 5 (1982)].


Male Balb/c strain mice (7-week-old) (Charles River Co.) were sensitized with 1×10^8 sheep erythrocytes (product of Biotest Research Institute) administered via the caudal vein, and the spleens were
 10 extirpated after 6 or 7 days after the sensitization. The extirpated spleens were immersed in Hanks' solution (Nissui Seiyaku) to make a cell suspension, which was then filtered, followed by centrifugal separation at 1200 rpm for 5 minutes. After centrifugal separation, the supernatant was discarded and the precipitate was treated with Tris-NH₄Cl solution to remove the erythrocytes, and then washed three times with Hanks' solution. After discarding the supernatant, the cells were suspended in an RPMI-1640 medium (Nissui
 15 Seiyaku) containing 10% bovine fetal serum (Gibco Co.), 50 µg/ml of streptomycin (Meiji Seika), 50 µU/ml of penicillin (Meiji Seika) and 2-mercaptoethanol (5×10^{-5} M). In each well of a micro culture plate (NUNK Co., Ltd., 24 wells) were put 2 ml of the mixture of the cell suspension containing 1×10^7 of spleen cells, 5×10^6 sheep erythrocytes and a test compound solution (10^{-6} M) obtained by diluting the test compound dissolved in dimethylsulfoxide (10^{-2} M) with the above mentioned RPMI-1640, and the cells were cultured
 20 at 37 °C for 5 days.

After the completion of the culturing, the cells were subjected to centrifugal separation at 2000 rpm for 5 minutes, and the resulting supernatant was removed. The precipitate was suspended in 1 ml of Hanks' solution, again subjected to centrifugal separation, suspended in 1 ml of Hanks' solution, and then, 50 µl of the suspension and 50 µl of sheep erythrocytes were added to 400 µl of 0.25% agarose/Hanks' solution
 25 heated to 50 °C in advance, and the mixture was scattered on a glass slide, placed on a plaque assay plate, and together with guinea pig complement (Cedarlane Institute) diluted 40-fold with a phosphate buffer solution, incubated at 37 °C for 1 to 2 hours. The number of the appearing direct plaque cells (direct PFC count) in suspension was counted.

The inhibition rate of the antibody production of the test compound was determined by the following
 30 equation.

$$\text{inhibition rate(\%)} = \frac{\text{PFC count in control} - \text{PFC count in the presence of test compound}}{\text{PFC count in control}} \times 100$$

The compound used for comparison was 5,6-dihydro-9-fluoro-3-phenylbenz[c]acridine-7-carboxylic acid [Japanese Published Unexamined Patent Application No. 233661/90, hereinafter referred to as Compound
 40 (A)] represented by formula (A).



(A)

55 PFC count in control means PFC count in the absence of the test compound (dimethylsulfoxide alone). The results are shown in Table 2.

Table 2

| Compound No. | Concentration (M) | Inhibition rate (%) |
|--------------|-------------------|---------------------|
| 2 | 10^{-5} | 99.4 |
| | 10^{-6} | 94.4 |
| | 10^{-7} | 57.1 |
| 3 | 10^{-5} | 83.5 |
| | 10^{-6} | 80.3 |
| | 10^{-7} | 55.4 |
| 5 | 10^{-5} | 98.7 |
| | 10^{-6} | 64.6 |
| 7 | 10^{-5} | 98.1 |
| | 10^{-6} | 75.3 |
| 8 | 10^{-5} | 98.7 |
| | 10^{-6} | 80.2 |
| A | 10^{-5} | 78.6 |
| | 10^{-6} | 45.9 |

Test Example 2:


Prophylactic effect against adjuvant arthritis

The experiment was carried out by using groups of 7-weeks-old female Lewis rats (Charles River Co.), each group consisting of 8 rats. Following the method of Newbould B.B. [Brit. J. Pharmacol., 21, 127 (1963)], *Mycobacterium butyricum* (killed and dried) (Difco Co.) suspended in liquid paraffin (0.6 mg/0.1 ml) was subcutaneously injected, as an adjuvant, into right hind paw of rats, hind paws volumes of which were measured in advance. After the injection, the hind paws volumes were measured using a plethysmograph (Unicom Co., Ltd., TK-101), and the swelling rates were determined by comparing each of the right and left hind paws volumes before the injection with that after the injection.

The test compound (Compound 3) was suspended in a 5% arabic gum solution and orally administered once a day on days 0 to 4, days 7 to 11 and days 14 to 16 provided the day of injection of the adjuvant was counted as day 0.

To the control group was orally administered only a 5% arabic gum solution.

The compound used for comparison was sodium 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinolinecarboxylate [Japanese Published Unexamined Patent Application No. 313428/89, hereinafter referred to as Compound (B)] represented by formula (B).



(B)

The results are shown in Figs. 1 and 2.

Depending on the pharmaceutical effects, Compound (I) and its pharmaceutically acceptable salt can be used as they are or in various preparation forms for the desired purpose of administration. The pharmaceutical composition of the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or its pharmaceutically acceptable salt as an active ingredient with a pharmaceutically acceptable carrier. The carrier may be in any of a wide variety of forms, depending on the most preferable form of preparation for administration. The pharmaceutical compositions are preferably in a unit dosage form suitable for oral administration or injection.

In the preparation of pharmaceutical compositions for oral administration, any useful, pharmaceutically acceptable carrier can be used. For example, a liquid preparation for oral administration such as suspension and a syrup can be prepared using water; a sugar such as sucrose, sorbitol and fructose; a glycol such as polyethylene glycol and propylene glycol; an oil such as sesame oil, olive oil and soybean oil; an antiseptic such as alkyl p-hydroxybenzoate; and a flavor such as strawberry flavor and peppermint flavor. Powders, pills, capsules and tablets may be prepared using an excipient such as lactose, glucose, sucrose and mannitol; a disintegrator such as starch and sodium alginate; a lubricant such as magnesium stearate and talc; a binder such as polyvinyl alcohol, hydroxypropyl cellulose and gelatin; a surfactant such as fatty acid esters; and a plasticizer such as glycerin. Tablets and capsules are the most useful oral unit dose forms, since their administration is easy. In the preparation of tablets or capsules, a solid pharmaceutical carrier is used.

A solution for injection may be prepared using a carrier such as distilled water; a saline solution, a glucose solution and a mixture of a saline solution and a glucose solution.

Compound (I) or its pharmaceutically acceptable salts may be administered either orally or parenterally by injection. The effective dose and the administration schedule of Compound (I) or its pharmaceutically acceptable salts vary depending on the mode of administration, age, weight and conditions of a patient, etc. However, it is generally preferred to administer Compound (I) or its pharmaceutically acceptable salts in a dose of 1 to 50 mg/kg per day in 3 to 4 parts.

Brief Description of the Drawings

Fig. 1 shows the swelling rates of the rats with right hind paw treated with an adjuvant.

In the figure, -○- represents the swelling rates of the control group, -Δ- represents the swelling rates of a comparison compound-administered group (dose: 3 mg/kg), -□- represents the swelling rates of a comparison compound-administered group (dose: 10 mg/kg), -▲- represents the swelling rates of a test compound-administered group (dose: 1 mg/kg), and -■- represents the swelling rates of a test compound-administered group (dose: 3 mg/kg).

Fig. 2 shows the swelling rates of the rats with the left hind paw untreated with an adjuvant.

In the figure, -○- represents the swelling rates of the control group, -Δ- represents the swelling rates of a comparison compound-administered group (dose: 3 mg/kg), -□- represents the swelling rates of a comparison compound-administered group (dose: 10 mg/kg), -▲- represents the swelling rates of a test compound-administered group (dose: 1 mg/kg), and -■- represents the swelling rates of a test compound-administered group (dose: 3 mg/kg).

Certain embodiments of the present invention are illustrated in the following Examples, Reference Examples and Preparation Examples.

Best Mode for Carrying Out the Invention

Example 1

8-Fluoro-3-(2-fluorophenyl)-5H-indeno[1,2-b]quinoline-6-carboxylic acid (Compound 1)

In 1 ml of water containing 650 mg (10 mmol) of potassium hydroxide was dissolved 330 mg (2 mmol) of 5-fluoroisatin, and 450 mg (2 mmol) of Compound c obtained in Reference Example 3 and dissolved in 5 ml of dioxane-ethanol (2:3) was added thereto. After heating to reflux for 3 hours, the solvent was distilled off and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, and the precipitated crystals were filtered off. The obtained crystals were washed with water, dried and recrystallized from dimethylformamide-water to obtain 313 mg (42% yield) of the desired compound.

Melting point: >300 °C

| Elemental analysis (%): $C_{23}H_{13}F_2NO_2 \cdot 0.5H_2O$ | | | |
|---|----------|---------|--------|
| Calcd. | C 72.25, | H 3.69, | N 3.66 |
| Found | C 72.35, | H 3.39, | N 4.07 |

IR (KBr) cm^{-1} : 1705, 1620, 1505, 1240

NMR (DMSO- d_6), δ (ppm): 8.35-8.21(m, 3H), 7.91(s, 1H), 7.78-7.61(m, 3H), 7.53-7.33(m, 3H), 4.40(s, 2H)

MS (m/e): 373 (M^+), 328 [(M-COOH) $^+$]

Example 2

5,6-Dihydro-9-fluoro-3-(2-fluorophenyl)benz[c]acridine-7-carboxylic acid (Compound 2)

In 24 ml of ethanol were dissolved 2.66 g (16 mmol) of Compound h obtained in Reference Example 8 and 3.81 g (16 mmol) of 5-fluoroisatin, and 12 ml of water containing 4.22 g (80 mmol) of potassium hydroxide was added thereto. After heating to reflux for 60 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, the precipitated crystals were filtered off and then washed with ether. The obtained crystals were recrystallized from dimethylformamide-water to obtain 2.6 g (43% yield) of the desired compound.

Melting point: $>300^\circ C$

| Elemental analysis (%): $C_{24}H_{15}F_2NO_2 \cdot 0.2H_2O$ | | | |
|---|----------|---------|--------|
| Calcd. | C 73.73, | H 3.97, | N 3.58 |
| Found | C 73.65, | H 3.73, | N 3.67 |

IR (KBr) cm^{-1} : 3400, 1718, 1615, 1502, 1420

NMR (DMSO- d_6), δ (ppm): 8.52(1H, d, J=8Hz), 8.23-8.17(1H, m), 7.95-7.32(8H, m), 3.21-3.07(4H, m)

MS (m/e): 387 (M^+)

Example 3

6,7-Dihydro-10-fluoro-3-(2-fluorophenyl)-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid (Compound 3)

In 4 ml of ethanol were dissolved 0.62 g (2.4 mmol) of Compound m obtained in Reference Example 13 and 0.41 g (2.4 mmol) of 5-fluoroisatin, and 2 ml of water containing 0.67 g (12 mmol) of potassium hydroxide was added thereto. After heating to reflux for 50 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, the precipitated crystals were filtered off and then washed with ether. The obtained crystals were recrystallized from dimethylformamide-water to obtain 445 mg (46% yield) of the desired compound.

Melting point: $>300^\circ C$

| Elemental analysis (%): $C_{25}H_{17}F_2NO_2 \cdot 0.4H_2O$ | | | |
|---|----------|---------|--------|
| Calcd. | C 73.49, | H 4.39, | N 3.43 |
| Found | C 73.55, | H 4.04, | N 3.34 |

IR (KBr) cm^{-1} : 2940, 2860, 1730, 1625, 1500, 1480, 1240

NMR (DMSO- d_6), δ (ppm): 8.24-8.19(1H, m), 7.87(1H, d, J=8Hz), 7.79-7.32(8H, m), 2.89-2.61(4H, m), 2.26-2.21(2H, m)

MS (m/e): 401 (M^+), 356

Example 4

11-Fluoro-3-(2-fluorophenyl)-5,6,7,8-tetrahydrobenzo[7,8]cycloocta[1,2-b]quinoline-9-carboxylic acid (Compound 4)

In 7 ml of ethanol were dissolved 0.67 g (2.5 mmol) of Compound n obtained in Reference Example 14 and 0.41 g (2.5 mmol) of 5-fluoroisatin, and 7 ml of 6 N potassium hydroxide was added thereto. After heating to reflux for 24 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, and the precipitated crystals were filtered off. The obtained residue was separated and purified by silica gel column chromatography [elution solvent: chloroform-methanol-acetic acid (100:1:0.1)], and then recrystallized from ethanol to obtain 0.60 g (58% yield) of the desired compound.

Melting point: >300 °C

| Elemental analysis (%): C ₂₆ H ₁₉ F ₂ NO ₂ •0.5H ₂ O | | | |
|---|----------|---------|--------|
| Calcd. | C 73.58, | H 4.75, | N 3.30 |
| Found | C 73.27, | H 4.54, | N 3.38 |

IR (KBr)cm⁻¹: 2928, 1702, 1625, 1501, 1486

NMR (DMSO-d₆), δ (ppm): 8.23-8.17(1H, m), 7.79-7.32(9H, m), 3.08-2.85(2H, m), 2.34-1.65(6H, m)

MS (m/e): 415 (M⁺)

Example 5

5,6-Dihydro-9-fluoro-3-(2-fluorophenyl)-5-methylbenz[c]acridine-7-carboxylic acid (Compound 5)

In 15 ml of ethanol were dissolved 1.26 g (5.0 mmol) of Compound p obtained in Reference Example 16 and 0.82 g (5.0 mmol) of 5-fluoroisatin, and 4 ml of water containing 1.39 g (25 mmol) of potassium hydroxide was added thereto. After heating to reflux for 45 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, the precipitated crystals were filtered off and then washed with ether. The obtained crystals were recrystallized from ethanol to obtain 0.85 g (43% yield) of the desired compound.

Melting point: 274.1-277.4 °C

| Elemental analysis (%): C ₂₅ H ₁₇ F ₂ NO ₂ •0.4H ₂ O | | | |
|---|----------|---------|--------|
| Calcd. | C 73.49, | H 4.39, | N 3.43 |
| Found | C 73.34, | H 4.11, | N 3.72 |

IR (KBr)cm⁻¹: 2364, 1626, 1502, 1408, 1366, 1247

NMR (DMSO-d₆), δ (ppm): 8.54(1H, d, J=8Hz), 8.23-8.17(1H, m), 7.76-7.32(8H, m), 3.49-3.23(2H, m), 3.06-2.97(1H, m), 1.22(3H, d, J=7Hz)

MS (m/e): 401 (M⁺), 386

Example 6

5,6-Dihydro-5-ethyl-9-fluoro-3-(2-fluorophenyl)benz[c]acridine-7-carboxylic acid (Compound 6)

In 4 ml of ethanol were dissolved 0.62 g (2.4 mmol) of Compound r obtained in Reference Example 18 and 0.41 g (2.4 mmol) of 5-fluoroisatin, and 2 ml of water containing 0.67 g (12 mmol) of potassium hydroxide was added thereto. After heating to reflux for 50 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, the precipitated crystals were filtered off and then washed with ether. The obtained crystals were recrystallized from dimethylformamide-water to obtain 445 mg (46% yield) of the desired compound.

Melting point: 236.5-237.0 °C

| Elemental analysis (%): $C_{26}H_{19}F_2NO_2 \cdot 0.6H_2O$ | | | |
|---|----------|---------|--------|
| Calcd. | C 73.26, | H 4.78, | N 3.29 |
| Found | C 73.39, | H 4.62, | N 3.28 |

IR (KBr) cm^{-1} : 2960, 1720, 1620, 1566, 1483

NMR (DMSO- d_6), δ (ppm): 8.52(1H, d, $J=8Hz$), 8.17-8.12(1H, m), 7.70-7.32(8H, m), 3.19-2.95(3H, m), 1.44-1.31(2H, m), 0.88(3H, t, $J=7Hz$)

MS (m/e): 415 (M^+), 386

Example 7

5,6-Dihydro-5,5-dimethyl-9-fluoro-3-(2-fluorophenyl)benz[c]acridine-7-carboxylic acid (Compound 7)

In 15 ml of ethanol were dissolved 2.25 g (8.39 mmol) of Compound u obtained in Reference Example 21 and 2.25 g (8.39 mmol) of 5-fluoroisatin, and 5 ml of water containing 2.14 g (41.9 mmol) of potassium hydroxide was added thereto. After heating to reflux for 20 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer, the precipitated crystals were filtered off and then washed with ether. The obtained crystals were recrystallized from ethanol to obtain 0.78 g (22% yield) of the desired compound.

Melting point: 269.2-272.4 °C

| Elemental analysis (%): $C_{26}H_{19}F_2NO_2 \cdot 0.3H_2O$ | | | |
|---|----------|---------|--------|
| Calcd. | C 74.02, | H 4.69, | N 3.33 |
| Found | C 74.20, | H 4.40, | N 3.59 |

IR (KBr) cm^{-1} : 1599, 1503, 1408, 1246

NMR (DMSO- d_6), δ (ppm): 8.58(1H, d, $J=8Hz$), 8.22-8.16(1H, m), 7.75-7.32(8H, m), 3.06(2H, s), 1.32-1.30(6H, s)

MS (m/e): 415 (M^+), 400

Example 8

5,6-Dihydro-9-fluoro-3-(2-fluorophenyl)-6-methylbenz[c]acridine-7-carboxylic acid (Compound 8)

In 10 ml of ethanol were dissolved 1.50 g (5.90 mmol) of Compound x obtained in Reference Example 24 and 0.97 g (5.90 mmol) of 5-fluoroisatin, and 3 ml of water containing 1.65 g (29.5 mmol) of potassium hydroxide was added thereto. After heating to reflux for 60 hours, the solvent was distilled off, and ether was added thereto, followed by extraction with water. Hydrochloric acid was added to the aqueous layer and the precipitated crystals were filtered off. The obtained residue was separated and purified by silica gel column chromatography [elution solvent: chloroform-methanol-acetic acid (100:1:0.1)], and then recrystallized from ethanol to obtain 0.32 g (14% yield) of the desired compound.

Melting point: 257.4-260.3 °C

| Elemental analysis (%): $C_{25}H_{17}F_2NO_2 \cdot 0.2H_2O$ | | | |
|---|----------|---------|--------|
| Calcd. | C 74.14, | H 4.33, | N 3.46 |
| Found | C 74.18, | H 4.62, | N 3.29 |

IR (KBr) cm^{-1} : 2360, 1703, 1560, 1506, 1485, 1239

NMR (CDCl₃), δ (ppm): 8.58(1H, d, $J=8Hz$), 8.24-8.18(1H, m), 7.64-7.15(8H, m), 3.58(1H, brs), 3.31-3.23(1H, m), 2.84-2.78(1H, m), 1.20(3H, d, $J=7Hz$)

MS (m/e): 401 (M^+), 386

Example 9

6,7-Dihydro-10-fluoro-3-(2-fluorophenyl)-5-methyl-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid (Compound 9)

In 3 ml of water containing 1.0 g (15.3 mmol) of potassium hydroxide was dissolved 0.51 g (3.06 mmol) of 5-fluoroisatin, and 0.82 g (3.06 mmol) of Compound z obtained in Reference Example 26 and dissolved in 6 ml of ethanoldioxane (5:1) was added thereto. After heating to reflux for 5 days, the solvent was distilled off, water-ether was added to the residue thereof for extraction, and the aqueous layer was washed with ether. The aqueous layer was filtered through celite. Acetic acid was added to the filtrate, and the precipitated crystals were filtered off. The obtained crystals were dried and then recrystallized from dimethylformamide-water to obtain 0.42 g (32% yield) of the desired compound.

Melting point: >300 °C

15

| Elemental analysis (%): C ₂₆ H ₁₉ F ₂ NO ₂ • 0.2H ₂ O | | | |
|--|----------|---------|--------|
| Calcd. | C 74.52, | H 4.67, | N 3.34 |
| Found | C 74.59, | H 4.57, | N 3.25 |

20

IR (KBr)cm⁻¹: 1712, 1628, 1502, 1243, 1216

NMR (DMSO-d₆), δ (ppm): 8.24-8.18(1H, m), 7.85-7.33(10H, m), 2.89-2.81(1H, m), 2.70-2.64(1H, m), 2.49-2.26(2H, m), 1.89-1.92(1H, m), 1.32(3H, d, J=7Hz)

MS (m/e): 415 (M⁺)

25

Example 10

6,7-Dihydro-10-fluoro-3-(2-fluorophenyl)-6-methyl-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid (Compound 10)

30

In the same manner as in Example 9 except for using 0.45 g (2.69 mmol) of 5-fluoroisatin, 0.9 g (13.5 mmol) of potassium hydroxide and 0.72 g of Compound cc obtained in Reference Example 29, 0.38 g (34% yield) of the desired compound was obtained.

Melting point: >300 °C

35

| Elemental analysis (%): C ₂₆ H ₁₉ F ₂ NO ₂ • 0.2H ₂ O | | | |
|--|----------|---------|--------|
| Calcd. | C 74.52, | H 4.67, | N 3.34 |
| Found | C 74.53, | H 4.57, | N 3.35 |

40

IR (KBr)cm⁻¹: 1703, 1610, 1494, 1236

NMR (DMSO-d₆), δ (ppm): 8.24-8.19(1H, m), 7.88(1H, d, J=8Hz), 7.79-7.33(8H, m), 2.82-2.49(4H, m), 2.35-2.28(1H, m), 1.06(3H, d, J=7Hz)

MS (m/e): 415 (M⁺)

45

Example 11

6,7-Dihydro-6,8-dimethyl-10-fluoro-3-(2-fluorophenyl)-5H-benzo[6,7]cyclohepta[1,2-b]quinoline-8-carboxylic acid (Compound 11)

50

In the same manner as in Example 9 except for using 0.46 g (2.76 mmol) of 5-fluoroisatin, 0.91 g (13.8 mmol) of potassium hydroxide and 0.78 g of Compound ff obtained in Reference Example 32, 0.56 g (47% yield) of the desired compound was obtained.

Melting point: >300 °C

55

| Elemental analysis (%): C ₂₇ H ₂₁ F ₂ NO ₂ · 0.2H ₂ O | | | |
|--|----------|---------|--------|
| Calcd. | C 74.88, | H 4.98, | N 3.23 |
| Found | C 74.90, | H 4.94, | N 3.38 |

IR (KBr)cm⁻¹: 1684, 1648, 1508

NMR (DMSO-d₆), δ (ppm): 8.25-8.19(1H, m), 7.88(1H, d, J=8Hz), 7.80-7.33(8H, m), 2.50(2H, s), 2.37-(2H, s), 1.09(6H, s)

MS (m/e): 429 (M⁺)

Reference Example 1

6-(2-Fluorophenyl)-1-indanone (Compound a)

To 10.7 g (80 mmol) of aluminum trichloride suspended in 100 ml of dichloroethane was added 5.46 g (42.7 mmol) of ethylmalonyl chloride. To the mixture was added 7.0 g (40 mmol) of 2-fluorobiphenyl, and the mixture was stirred at room temperature for 4 hours. The reaction solution was poured into hydrochloric acid containing ice, and extracted with chloroform. The organic layer was washed with hydrochloric acid and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was separated and purified by silica gel column chromatography [elution solvent: hexane:ethyl acetate (30:1)], to obtain a mixture (70% yield) of ethyl 4-(2-fluorophenyl) benzoylacetate and ethyl 2-(2-fluorophenyl)benzoylacetate.

To 7.9 g of the above mentioned mixture dissolved in 30 ml of trifluoroacetic acid was added 10.6 ml (66 mmol) of triethylsilane, and the mixture was stirred at 70 °C for 2 hours. After the solvent was distilled off, chloroform and water were added to the residue for extraction. The organic layer was washed with an aqueous solution of sodium bicarbonate, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was separated and purified by silica gel column chromatography [elution solvent: hexane:ethyl acetate (30:1)], to obtain 6.1 g (81% yield) of a mixture of ethyl 4-(2-fluorophenyl)benzylacetate and ethyl 2-(2-fluorophenyl)benzylacetate.

To 5.9 g of the above mentioned mixture dissolved in 20 ml of dioxane was added 20 ml of an aqueous solution of 4 N sodium hydroxide, and the mixture was heated to reflux for 2 hours. The solvent was distilled off under reduced pressure, and 50 ml of water was added thereto. The mixture was washed with ether, 20 ml of 6 N hydrochloric acid was added to the aqueous layer for acidification, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 5.2 g (97% yield) of a mixture of 4-(2-fluorophenyl)benzylacetic acid and 2-(2-fluorophenyl)benzylacetic acid.

To 5.1 g of the above mentioned mixture was added 50 ml of polyphosphoric acid, and the mixture was stirred at 80 °C for 2 hours. The reaction product was poured into ice water and extracted with chloroform. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (30:1)], to obtain 2.9 g (54% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.93(1H, s), 7.81(1H, d, J=8Hz), 7.53-7.13(5H, m), 3.20(2H, t, J=6Hz), 2.75(2H, t, J=6Hz)

MS (m/e): 226 (M⁺)

Reference Example 2

5-(2-Fluorophenyl)indan (Compound b)

In 20 ml of trifluoroacetic acid was dissolved 1.6 g (7.1 mmol) of Compound a obtained in Reference Example 1 and 2.61 ml (16.3 mmol) of triethylsilane was added thereto. The mixture was stirred at 80 °C for 3 hours. The solvent was distilled off, and then chloroform and water were added to the residue for extraction. The organic layer was washed with an aqueous solution of sodium bicarbonate and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain 1.38 g (92% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.44-7.10(7H, m), 2.99-2.92(4H, m), 2.16-2.05(2H, q, J=7Hz)
 MS (m/e): 212 (M⁺)

Reference Example 3

5-(2-Fluorophenyl)-1-indanone (Compound c)

In 1 ml of propionic acid and 4 ml of acetic acid was dissolved 1.35 g of Compound b obtained in Reference Example 2, and 1.91 g (19.1 mmol) of chromic acid dissolved in 7.2 ml of acetic acid-water (7:1) was added thereto at 0 °C. The mixture was stirred at room temperature for 2 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was separated and purified by silica gel column chromatography [elution solvent: 4% ethyl acetate-hexane] to obtain 1.0 g (70% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.83(1H, d, J=8Hz), 7.66(1H, s), 7.56-7.18(5H, m), 3.21(2H, t, J=6Hz), 2.75(2H, t, J=6Hz)

MS (m/e): 226 (M⁺)

Reference Example 4

3-[4-(2-Fluorophenyl)benzoyl]propanoic acid (Compound d)

To 6.2 g (46.5 mmol) of aluminum trichloride suspended in 50 ml of dichloroethane were added 3.02 g (30.2 mmol) of succinic anhydride and 4.0 g (23.2 mmol) of 2-fluorobiphenyl were added thereto and the mixture was stirred at room temperature for 4 hours. The reaction solution was poured into hydrochloric acid containing ice, and extracted with chloroform. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then recrystallized from chloroform to obtain 5.6 g (89% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.15(2H, d, J=7Hz), 7.73-7.00(7H, m), 3.35(2H, t, J=7Hz), 2.85(2H, t, J=7Hz)

MS (m/e): 272 (M⁺), 255, 228

Reference Example 5

4-[4-(2-Fluorophenyl)phenyl]butanoic acid (Compound e)

In 25 ml of trifluoroacetic acid was dissolved 5.21 g (19.1 mmol) of Compound d obtained in Reference Example 4, and 7.5 ml (46.5 mmol) of triethylsilane was added thereto. The mixture was stirred at 70 °C for 6 hours. The solvent was distilled off, and then chloroform and water were added to the residue for extraction. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was separated and purified by silica gel column chromatography [elution solvent: ethyl acetate-hexane (4:1)] to obtain 4.72 g (97% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.65-6.93(8H, m), 2.80(2H, t, J=6Hz), 2.31(2H, t, J=6Hz), 2.21-1.81(2H, m)

MS (m/e): 258 (M⁺)

Reference Example 6

3,4-Dihydro-7-(2-fluorophenyl)-1-(2H)-naphthalenone (Compound f)

To 4.72 g (18.4 mmol) of Compound e obtained in Reference Example 5 was added 50 ml of polyphosphoric acid, and the mixture was stirred at 70 °C for 4 hours. The reaction product was poured into ice water and extracted with chloroform. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 4.11 g (94% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.15(1H, s), 7.71-6.90(6H, m), 2.93(2H, t, J=5Hz), 2.60(2H, t, J=5Hz), 2.30-1.92(2H, m)

MS (m/e): 240 (M⁺)

Reference Example 7

6-(2-Fluorophenyl)-1,2,3,4-tetrahydronaphthalene (Compound g)

5 in 40 ml of trifluoroacetic acid was dissolved 9.45 g (39.6 mmol) of Compound f obtained in Reference Example 6, and 15.3 ml (95.2 mmol) of triethylsilane was added thereto. The mixture was stirred at 70 °C for 1 hour. The solvent was distilled off, and then chloroform and water were added to the residue for extraction. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the desired compound, which was used in the
 10 next reaction with no further purification.

NMR (CDCl₃), δ (ppm): 7.48-6.87(7H, m), 2.90-2.60(4H, m), 1.90-1.55(4H, m)

MS (m/e): 226 (M⁺)

Reference Example 8

3,4-Dihydro-6-(2-fluorophenyl)-1(2H)-naphthalenone (Compound h)

In 6 ml of propionic acid and 23 ml of acetic acid was dissolved 4.5 g of Compound g obtained in Reference Example 7, and 5.93 g (59.3 mmol) of chromic acid dissolved in 24 ml of acetic acid-water (7:1) was added thereto at 0 °C. The mixture was stirred at room temperature for 12 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (9:1)] to obtain 2.75 g (58% yield from Compound f) of the desired compound.
 20

25 NMR (CDCl₃), δ (ppm): 8.10(1H, d, J=8Hz), 7.60-6.95(6H, m), 3.01(2H, t, J=6Hz), 2.69(2H, t, J=6Hz), 2.31-2.00(2H, m)

MS (m/e): 240 (M⁺)

Reference Example 9

3-[4-(2-Fluorophenyl)benzoyl]butanoic acid (Compound i)

To 6.03 g (45.2 mmol) of aluminum trichloride suspended in 50 ml of dichloroethane were added 2.58 g (22.6 mmol) of anhydrous glutaric acid and 3.0 g (17.4 mmol) of 2-fluorobiphenyl, and the mixture was
 35 stirred at room temperature for 3 hours. The reaction solution was poured into hydrochloric acid containing ice, and extracted with chloroform. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then recrystallized from ethyl acetate to obtain 1.53 g (31% yield) of the desired compound.

40 NMR (DMSO-d₆), δ (ppm): 8.05(1H, d, J=8Hz), 7.76-7.21(7H, m), 3.10(2H, t, J=6Hz), 2.33(2H, t, J=6Hz), 2.10-1.75(2H, m)

MS (m/e): 286 (M⁺)

Reference Example 10

5-[4-(2-Fluorophenyl)phenyl]pentanoic acid (Compound j)

In 20 ml of trifluoroacetic acid was dissolved 3.8 g (13.3 mmol) of Compound i obtained in Reference Example 9, and 5.22 ml (32.5 mmol) of triethylsilane was added thereto. The mixture was stirred at 70 °C for 3 hours. The solvent was distilled off, and then chloroform and water were added to the residue for
 50 extraction. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then recrystallized from methylene chloride-hexane to obtain 2.7 g (75% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.56-6.99(8H, m), 2.83-2.57(2H, m), 2.52-2.23(2H, m), 1.93-1.50(4H, m)

MS (m/e): 272 (M⁺), 254

Reference Example 11

8-(2-Fluorophenyl)-1-benzosuberone (Compound k)

5 To 2.70 g (9.9 mmol) of Compound j obtained in Reference Example 10 was added 50 ml of polyphosphoric acid, and the mixture was stirred at 110 °C for 4 hours. The reaction product was poured into ice water and extracted with chloroform. The organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 2.41 g (96% yield) of the desired compound.

10 NMR (CDCl₃), δ (ppm): 7.91(1H, s), 7.65(1H, d, J=8Hz), 7.51-7.10(5H, m), 2.98(2H, t, J=7Hz), 2.78(2H, t, J=7Hz), 1.99-1.81(4H, m)

MS (m/e): 254 (M⁺)

Reference Example 12

15

7-(2-Fluorophenyl)-1H-2,3,4,5-tetrahydrobenzocycloheptene (Compound l)

In 20 ml of trifluoroacetic acid was dissolved 2.36 g (9.2 mmol) of Compound k obtained in Reference Example 11, and 3.4 ml (21 mmol) of triethylsilane was added thereto. The mixture was stirred at 70 °C for 3 hours. The solvent was distilled off, and then chloroform and water were added to the residue for extraction. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the subject compound, which was used in the next reaction with no further purification.

20 NMR (CDCl₃), δ (ppm): 7.66-6.80(7H, m), 3.19-2.48(4H, m), 2.15-1.24(6H, m)

25 MS (m/e): 240 (M⁺)

Reference Example 13

7-(2-Fluorophenyl)-1-benzosuberone (Compound m)

30

In a mixture of 3 ml of propionic acid and 12 ml of acetic acid was dissolved 2.0 g of Compound l obtained in Reference Example 12, and 2.5 g (24.9 mmol) of chromic acid dissolved in 12 ml of acetic acid-water (7:1) was added thereto at 0 °C, and the mixture was stirred at room temperature for 8 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (9:1)] to obtain 0.43 g (20% yield from Compound l) of the desired compound.

35 NMR (CDCl₃), δ (ppm): 7.79(1H, d, J=8Hz), 7.57-7.00(6H, m), 2.97(2H, t, J=7Hz), 2.75(2H, t, J=7Hz), 2.04-1.65(4H, m)

40 MS (m/e): 254 (M⁺)

Reference Example 14

45 8-(2-Fluorophenyl)-1-benzocyclooctanone (Compound n)

In 10 ml of dimethylformamide were dissolved 2.0 g (7.9 mmol) of 8-bromo-1-benzocyclooctanone, 0.27 g (0.23 mmol) of tetrakis(triphenylphosphine) palladium and 2.0 g (8.6 mmol) of silver oxide, 4.6 g (11.9 mmol) of o-fluorophenyltributyl tin was added thereto, and the mixture was stirred under an argon atmosphere at 120 °C for 2 hours. After cooling, an aqueous solution of ammonium fluoride was added to the reaction solution, and then stirred at room temperature for 12 hours. The reaction solution was filtered through celite, washed with ethyl acetate and water, and then extracted. The organic layer was washed with saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (9:1)] to obtain 0.84 g (40%) of the desired compound.

50 NMR (CDCl₃), δ (ppm): 7.79(1H, d, J=8Hz), 7.49-7.12(6H, m), 3.13(2H, t, J=5Hz), 2.98(2H, t, J=5Hz), 1.94-1.80(4H, m), 1.62-1.51(2H, m)

55 MS (m/e): 268 (M⁺)

Reference Example 15

7-(2-Fluorophenyl)-1-methyl-1,2,3,4-tetrahydronaphthalene (Compound o)

To 12 ml of dimethylsulfoxide was added 1.0 g (25.0 mmol) of 60% sodium hydroxide, and the mixture was stirred at 60°C for 1 hour. After allowing the solution to room temperature, 9.08 g (25.4 mmol) of methyltriphenylphosphonium bromide and 12 ml of tetrahydrofuran were added thereto. The mixture was stirred at room temperature for 20 minutes, 3.00 g (12.5 mmol) of Compound f obtained in Reference Example 6 dissolved in 15 ml of tetrahydrofuran was further added thereto, and the mixture was stirred at room temperature for 3 hours. Ether and water were added to the reaction solution for extraction. The organic layer was washed with saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, the residue was dissolved in 30 ml of ethanol, 150 mg of palladium/carbon was added thereto, and the mixture was stirred under a hydrogen atmosphere at room temperature for 4 hours. The mixture was then filtered through celite and the solvent was distilled off. The residue was separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain 1.80 g (60%) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.45-7.09(7H, m), 3.00-2.78(3H, m), 1.98-1.53(4H, m), 1.33(3H, d, J = 7Hz)

MS (m/e): 240 (M⁺), 225

Reference Example 16

3,4-Dihydro-6-(2-fluorophenyl)-4-methyl-1(2H)-naphthalenone (Compound p)

In a mixture of 3 ml of propionic acid and 10 ml of acetic acid was dissolved 1.85 g (7.7 mmol) of Compound o obtained in Reference Example 15, and 2.5 g (25 mmol) of chromic acid dissolved in 12 ml of acetic acid-water (7:1) was added thereto at 0°C. The mixture was stirred at room temperature for 4 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (10:1)] to obtain 0.88 g (45% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.10(1H, d, J = 8Hz), 7.51-7.13(6H, m), 3.19-1.88(5H, m), 1.43(3H, d, J = 7Hz)

MS (m/e): 254 (M⁺), 226

Reference Example 17

1-Ethyl-7-(2-fluorophenyl)-1,2,3,4-tetrahydronaphthalene (Compound q)

To 45 ml of dimethylsulfoxide was added 1.33 g (33.3 mmol) of 60% sodium hydride, and the mixture was stirred at 60°C for 1 hour. After allowing the solution to room temperature, 12.5 g (33.8 mmol) of methyltriphenylphosphonium bromide and 45 ml of tetrahydrofuran were added thereto, the mixture was stirred at room temperature for 20 minutes, 4.00 g (16.6 mmol) of Compound f obtained in Reference Example 6 dissolved in 15 ml of tetrahydrofuran was further added thereto, and the mixture was stirred at room temperature for 5 hours. Ether and water were added to the reaction solution for extraction. The organic layer was washed with saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, the residue was dissolved in 80 ml of ethanol, 168 mg of platinum dioxide was added thereto, and the mixture was stirred under a hydrogen atmosphere at room temperature for 4 hours. The mixture was then filtered through celite and the solvent was distilled off. The residue was separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain 3.26 g (77%) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.45-7.08(7H, m), 2.80-2.72(3H, m), 1.91-1.53(6H, m), 0.99(3H, t, J = 7Hz)

MS (m/e): 254 (M⁺)

Reference Example 18

3,4-Dihydro-4-ethyl-6-(2-fluorophenyl)-1(2H)-naphthalenone (Compound r)

In a mixture of 4 ml of propionic acid and 15 ml of acetic acid was dissolved 3.26 g (12.8 mmol) of Compound q obtained in Reference Example 17, 4.09 g (40.9 mmol) of chromic acid dissolved in 24 ml of acetic acid-water (7:1) was added thereto at 0°C, and the mixture was stirred at room temperature for 4 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (30:1)] to obtain 1.39 g (41% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.10(1H, d, J=8Hz), 7.50-7.13(6H, m), 2.94-1.70(7H, m), 1.05(3H, t, J=7Hz).

MS (m/e): 268 (M⁺)

Reference Example 19

5-[4-(2-Fluorophenyl)phenyl]-2-methyl-2-pentanol (Compound s)

In 50 ml of tetrahydrofuran was dissolved 5.00 g (19.4 mmol) of Compound e obtained in Reference Example 5, 40 ml (120 mmol) of an ether solution with 3 M concentration of methyl magnesium bromide was added thereto at 0°C, and then the mixture was heated to reflux for 1 hour. An aqueous solution of ammonium chloride and ether were added to the reaction solution for extraction. The organic layer was washed with saline and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then the residue was separated and purified by silica gel column chromatography [elution solvent: ethyl acetate-hexane (8:1)] to obtain 3.67 g (70% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.49-7.09(7H, m), 2.66(2H, t, J=7Hz), 1.78-1.51(m, 4H), 1.21(s, 6H)

MS (m/e): 258 (M⁺), 199

Reference Example 20

7-(2-Fluorophenyl)-1,1-dimethyl-1,2,3,4-tetrahydronaphthalene (Compound t)

In 40 ml of dichloroethane was dissolved 3.67 g (13.5 mmol) of Compound s obtained in Reference Example 19, 2.0 g (15.0 mmol) of aluminum trichloride was added thereto, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was poured into ice water, and chloroform was added thereto for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain 2.41 g (96% yield) of the desired compound. The solvent was distilled off under reduced pressure, and then, chloroform and water were added to the residue for extraction. The organic layer was washed with water, and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain 3.00 g (88% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.77-7.33(7H, m), 3.05(2H, t, J=6Hz), 2.10-1.92(4H, m), 1.58(6H, s)

MS (m/e): 254 (M⁺), 239

Reference Example 21

3,4-Dihydro-4,4-dimethyl-6-(2-fluorophenyl)-1(2H)-naphthalenone (Compound u)

In 3.5 ml of propionic acid and 17 ml of acetic acid was dissolved 2.80 g (11.1 mmol) of Compound t obtained in Reference Example 20, 3.54 g (35.4 mmol) of chromic acid dissolved in 14 ml of acetic acid-water (7:1) was added thereto at 0°C, and the mixture was stirred at room temperature for 4 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (10:1)] to obtain 2.25 g (76% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.09(1H, d, J=8Hz), 7.61-7.14(6H, m), 2.76(t, J=6Hz), 2.06(2H, t, J=6Hz), 1.44-(6H, s)

MS (m/e): 268 (M⁺), 253, 225

5 Reference Example 22

3,4-Dihydro-7-(2-fluorophenyl)-2-methyl-1(2H)-naphthalenone (Compound v)

In 20 ml of toluene was dissolved 2.00 g (8.32 mmol) of Compound f obtained in Reference Example 6,
10 1.45 g (18.3 mmol) of potassium hydroxide, 0.22 g (0.83 mmol) of 18-crown-6 and 6.8 ml (110 mmol) of methyl iodide were added thereto, and the mixture was stirred at room temperature for 4 hours. Ammonium chloride and ethyl acetate were added to the reaction solution for extraction. The organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution
15 solvent: hexane-ethyl acetate (50:1)] to obtain 0.89 g (42% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.20(1H, s), 7.69-7.11(6H, m), 3.09-1.84(5H, m), 1.30(3H, d, J=7Hz)

- MS (m/e): 254 (M⁺), 212

Reference Example 23

20

7-(2-Fluorophenyl)-2-methyl-1,2,3,4-tetrahydronaphthalene (Compound w)

In 15 ml of trifluoroacetic acid was dissolved 2.16 g (8.49 mmol) of Compound v obtained in Reference Example 22, 3.26 ml (20.4 mmol) of triethylsilane was added thereto, and the mixture was stirred at 70 °C
25 for 30 minutes. The solvent was distilled off, and then chloroform and water were added to the residue for extraction. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure to obtain the desired compound, which was used in the next reaction with no further purification.

NMR (CDCl₃), δ (ppm): 7.46-7.09(7H, m), 2.92-1.38(7H, m), 1.08(3H, d, J=7Hz)

30 MS (m/e): 240 (M⁺), 198

Reference Example 24

3,4-Dihydro-6-(2-fluorophenyl)-3-methyl-1(2H)-naphthalenone (Compound x)

35

In a mixture of 2.7 ml of propionic acid and 10 ml of acetic acid was dissolved 2.3 g of Compound w obtained in Reference Example 23, 2.71 g (2.71 mmol) of chromic acid dissolved in 10 ml of acetic acid-water (7:1) was added thereto at 0 °C, and the mixture was stirred at room temperature for 3 hours. An aqueous solution of sodium sulfite and ethyl acetate were added to the reaction solution for extraction. The
40 organic layer was washed with saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (10:1)] to obtain 2.15 g (70% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 8.09(1H, d, J=8Hz), 7.50-7.13(6H, m), 3.05-2.32(5H, m), 1.17(3H, d, J=7Hz)

45 MS (m/e): 254 (M⁺), 212

Reference Example 25

8-(2-Fluorophenyl)-1-methyl-1H-2,3,4,5-tetrahydrobenzocycloheptene (Compound y)

50

In 20 ml of tetrahydrofuran was dissolved 2.50 g (9.84 mmol) of Compound k obtained in Reference Example 11, 6.7 ml (19.68 mmol) of an ether solution with 3 M concentration of methyl magnesium bromide was added thereto, and then the mixture was heated to reflux for 10 hours. The reaction solution was allowed to room temperature, a saturated aqueous solution of ammonium chloride was added thereto to
55 stop the reaction, and ether was added thereto for extraction. The organic layer was washed with water and with saturated saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (25:1)]. To 2.0 g of the obtained compound were added 2.85 ml (17.8

mmol) of triethylsilane and 10 ml of trifluoroacetic acid, and the mixture was stirred at 60 °C for 1 hour. The solvent was distilled off under reduced pressure, chloroform was added thereto for extraction and the organic layer was washed with water and dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain the desired compound, which was used in the next reaction with no further purification.

NMR (CDCl₃), δ (ppm): 7.47-7.08(7H, m), 3.09(1H, q, J=7Hz), 2.96-2.78(2H, m), 1.98-1.69(4H, m), 1.54-1.30(2H, m), 1.37(3H, d, J=7Hz)

MS (m/e): 254 (M⁺)

Reference Example 26

7-(2-Fluorophenyl)-5-methyl-1-benzosuberone (Compound z)

In a mixture of 1 ml of propionic acid and 10 ml of acetic acid was dissolved 1.60 g (6.29 mmol) of Compound y obtained in Reference Example 25, and 1.90 g (18.9 mmol) of chromic acid dissolved in 8 ml of acetic acid-water (7:1) was added thereto at 0 °C. The mixture was stirred at room temperature for 6 hours, and an aqueous solution of sodium sulfite was added thereto to stop the reaction. The solvent was distilled off under reduced pressure, and then ethyl acetate and water were added to the residue for extraction. The organic layer was washed with water and with saturated saline, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (25:1)] to obtain 0.35 g (21% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.64 (1H, d, J=8Hz), 7.49-7.13(6H, m), 3.21-3.13(1H, m), 2.82-2.58(2H, m), 2.08-1.83(2H, m), 1.78-1.55(2H, m), 1.42(3H, d, J=7Hz)

MS (m/e): 268 (M⁺)

Reference Example 27

8-(2-Fluorophenyl)-2-methyl-1-benzosuberone (Compound aa)

In 70 ml of toluene was dissolved 2.50 g (9.84 mmol) of Compound k obtained in Reference Example 11, 1.32 ml (14.8 mmol) of pyrrolidine and 50 mg of tosylic acid were added thereto, and the mixture was heated to reflux for 6 hours under azeotropic dehydration. The solvent was distilled off, the residue was allowed to room temperature, 100 ml of dioxane and 1.04 ml (16.7 mmol) of methyl iodide were added thereto, and the mixture was heated to reflux for 6 hours. The reaction solution was allowed to room temperature, 2 ml of water, and then 1 ml of acetic acid, were added thereto, and the mixture was stirred for 30 minutes. The solvent was distilled off under reduced pressure, and chloroform was added to the residue for extraction. The organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (30:1)] to obtain 1.66 g (63% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.85(1H, s), 7.48-7.10(6H, m), 3.06-2.93(3H, m), 2.12-1.61(4H, m), 1.24(3H, d, J=7Hz)

MS (m/e): 268 (M⁺)

Reference Example 28

8-(2-Fluorophenyl)-2-methyl-1H-2,3,4,5-tetrahydrobenzocycloheptene (Compound bb)

In 25 ml of trifluoroacetic acid was dissolved 2.98 g (11.1 mmol) of Compound aa obtained in Reference Example 27, 4.28 ml (26.6 mmol) of triethylsilane was added thereto, and the mixture was stirred at 70 °C for 2 hours. The solvent was distilled off, chloroform and water were added to the residue for extraction, and the organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain the desired compound, which was used in the next reaction with no further purification.

NMR (CDCl₃), δ (ppm): 7.43-7.10(7H, m), 2.81-2.71(4H, m), 1.99-1.44(5H, m), 0.97(3H, d, J=8Hz)
MS (m/e): 254 (M⁺)

Reference Example 29

7-(2-Fluorophenyl)-4-methyl-1-benzosuberone (Compound cc)

In 15 ml of acetic acid was dissolved 2.76 g (10.9 mmol) of Compound bb obtained in Reference Example 28, and 3.27 g (32.7 mmol) of chromic acid dissolved in 8 ml of acetic acid-water (7:1) was added thereto at 0°C. The mixture was stirred at room temperature for 6 hours, and an aqueous solution of sodium sulfite was added thereto to stop the reaction. The solvent was distilled off under reduced pressure, and then ethyl acetate and water were added to the residue for extraction. The organic layer was washed with water and with saturated saline, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (25:1) to obtain 0.60 g (21% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.80(1H, d, J=8Hz), 7.51-7.13(6H, m), 3.07-2.99(1H, m), 2.85-2.61(3H, m), 2.21-2.11 (1H, m), 2.02-1.90(1H, m), 1.47-1.35(1H, m), 1.04(3H, d, J=7Hz)
MS (m/e): 268 (M⁺)

Reference Example 30

2,2-Dimethyl-8-(2-fluorophenyl)-1-benzosuberone (Compound dd)

In 30 ml of tetrahydrofuran was dissolved 2.50 g (9.84 mmol) of Compound k obtained in Reference Example 11, 2.67 g (24.6 mmol) of potassium tert-butoxide was added thereto, and the mixture was stirred for 30 minutes. To the mixture was added 1.53 ml (24.6 mmol) of methyl iodide at 0°C, stirred at room temperature for 8 hours, and water was added thereto to stop the reaction. Ethyl acetate was added thereto for extraction, and the organic layer was washed with water and with saturated saline and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and then the residue was separated and purified by silica gel column chromatography [elution solvent: hexane-ethyl acetate (50:1)] to obtain 1.80 g (65% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.57-7.13 (7H, m), 2.81(2H, t, J=7Hz), 1.98-1.91(2H, m), 1.74-1.69(2H, m), 1.20-0.6H, s)

MS (m/e): 282 (M⁺)

Reference Example 31

2,2-Dimethyl-8-(2-fluorophenyl)-1H-2,3,4,5-tetrahydrobenzocycloheptene (Compound ee)

In 25 ml of trifluoroacetic acid was dissolved 2.22 g (7.87 mmol) of Compound dd obtained in Reference Example 30, 3.03 ml (18.9 mmol) of triethylsilane was added thereto, and the mixture was stirred at 70°C for 2 hours. The solvent was distilled off, chloroform and water were added to the residue for extraction, and the organic layer was washed with water and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and separated and purified by silica gel column chromatography [elution solvent: hexane] to obtain the desired compound, which was used in the next reaction with no further purification.

NMR (CDCl₃), δ (ppm): 7.45-7.08(7H, m), 2.81-2.70(4H, m), 1.69-1.47(4H, m), 0.86(6H, s)
MS (m/e): 268 (M⁺)

Reference Example 32

4,4-Dimethyl-7-(2-fluorophenyl)-1-benzosuberone (Compound ff)

In 15 ml of acetic acid was dissolved 2.10 g (7.84 mmol) of Compound ee obtained in Reference Example 31, and 2.35 g (23.5 mmol) of chromic acid dissolved in 8 ml of acetic acid-water (7:1) was added thereto at 0°C. The mixture was stirred at room temperature for 6 hours, and an aqueous solution of sodium sulfite was added thereto to stop the reaction. The solvent was distilled off under reduced pressure,

and then ethyl acetate and water were added to the residue for extraction. The organic layer was washed with water and with saturated saline, and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and then the residue was separated and purified by silica gel column chromatography. [elution solvent: hexane-ethyl acetate (25:1)] to obtain 0.79 g (36% yield) of the desired compound.

NMR (CDCl₃), δ (ppm): 7.81(1H, d, J=8Hz), 7.52-7.13(6H, m), 2.71-2.63(4H, m), 1.55-1.51(2H, m), 1.05-(6H, s)

MS (m/e): 282 (M⁺)

10 Preparation Example 1: Tablets

Tablets each having the following composition were prepared in a conventional manner.

| | | | |
|----|--------------|--------------------|--------|
| 15 | Prescription | Compound 1 | 10 mg |
| | | Lactose | 30 mg |
| | | Potato starch | 15 mg |
| | | Polyvinyl alcohol | 1.5 mg |
| | | Magnesium stearate | 0.5 mg |

20

Preparation Example 2: Capsules

Capsules each having the following composition were prepared in a conventional manner.

| | | | |
|----|--------------|--------------------|--------|
| 25 | Prescription | Compound 1 | 10 mg |
| | | Lactose | 100 mg |
| | | Magnesium stearate | 2.5 mg |
| | | | |

30

A mixture of the above ingredients was loaded into gelatin capsules.

Preparation Example 3: Injections

35 Injections having the following composition were prepared in a conventional manner.

| | | | |
|----|--------------|-----------------|-------|
| 40 | Prescription | Compound 1 | 10 mg |
| | | Sodium chloride | 20 mg |

40

To the ingredients was added distilled water for injection to make the total volume 5 ml (per ampule).


Industrial Applicability

45 According to the present invention, there can be provided novel tetracyclic compounds which are useful as immunosuppressive agents.

Claims

50 1. A novel tetracyclic compound represented by formula (I)

55



(wherein each of X^1 and X^2 independently represents hydrogen or lower alkyl; n represents an integer of 1 to 4), or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier.
3. Use of a compound as defined in claim 1 for the preparation of a pharmaceutical composition for use as an immunosuppressive.

FIG. 1





FIG. 2



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP93/00527

A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl⁵ C07D221/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl⁵ C07D221/18, A61K31/47

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| A | WO, A, 9200739 (Du Pont Merck Pharm, Co.), January 23, 1992 (23. 01. 92), & AU, A, 9183079 & US, A, 5135934 & US, A, 5190753 | 1 |
| A | US, A, 4918077 (Du Pont de Nemours), April 17, 1990 (17. 04. 90), & EP, A, 380038 & JP, A, 90-233661 & US, A, 5002954 | 1. |

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search

May 13, 1993 (13. 05. 93)

Date of mailing of the international search report

June 1, 1993 (01. 06. 93)

Name and mailing address of the ISA/

Japanese Patent Office

Facsimile No.

Authorized officer

Telephone No.